OCUL - Ocular Therapeutix Inc
Ocular Therapeutix Inc Logo

OCUL - Ocular Therapeutix Inc

https://www.ocutx.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Broadcom Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Broadcom ( NASDAQ:AVGO ) , Fractyl Health ( NASDAQ:GUTS )
Benzinga • 6 hours, 27 minutes ago • score: 0.16
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Chardan Capital analyst Daniil Gataulin initiated coverage on Ocular Therapeutix, Inc.
Neutral
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - Ocular Therapeutix ( NASDAQ:OCUL )
Benzinga • 2 months, 2 weeks ago • score: 0.08
BEDFORD, Mass., June 26, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's ...
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.

52W High
$13.85
52W Low
$5.79
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.50
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-6.06
EV/Revenue (<3 favorable)
36.22
P/S (TTM) (<3 favorable)
41.76
P/B (<3 favorable)
7.74
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
3.35%
Institutions (25–75% balanced)
90.81%
Shares Outstanding
173,995,000
Float
145,243,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
56,664,000
Gross Profit (TTM)
-121,314,000
EPS (TTM)
-1.26
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-5.03%
ROE (TTM) (>15% strong)
-0.63%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.18
Momentum
Bearish momentum
Value
0.3322
Previous
0.3544
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025